Mesoblast Limited · ASX:MSB
Mesoblast — Bell Potter Life Sciences Conference 2012
19 slides from Mesoblast's conference presentation, Nov 2, 2012
Slide 1: CEO Presentation, Bell Potter Life Sciences Conference
For personal use only CEO Presenta,on Bell Po0er Life Sciences Conference Melbourne, November 2012
Slide 2: Forward looking statements
Forward looking statements CAUTIONARY NOTE REGARDING FORWARD-‐LOOKING STATEMENTS For personal use only This presenta,on, including any comments made during or following the presenta,on, may contain forward-‐looking statements that are inherently subject to risks and uncertain,es, some of which can
Slide 3: Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) technology
Mesoblast’s proprietary Mesenchymal Precursor Cell (MPC) technology For personal use only 1. Patented adult stem cell technology pla4orm for Stro-‐1/Stro-‐3 cells 2. Highly purified popula?ons of earliest precursors of mesenchymal lineage cells 3. Scien?fic advantages based on high degree of potency
Slide 4: Leveraging Mesoblast's proprietary MPC technology
Leveraging Mesoblast’s proprietary MPC technology For personal use only § Mul?ple products, parallel ?meframes § Products specifically target major medical condi?ons where proprietary technology offers unique scien?fic and clinical advantages § Strong cash posi?on enables simultaneous development §
Slide 5: Diverse products in distinct areas
Diverse products in dis,nct areas For personal use only 1. Products in partnership with Teva, primarily in cardiovascular and neurological diseases 2. Products for intravenous delivery in type 2 diabetes and its complica?ons including kidney disease 3. Products delivered intravenously for immunologi
Slide 6: Corporate partnerships manage execution risk – Teva alliance
Corporate partnerships manage execu,on risk – Teva alliance For personal use only § Partnership focus on neurologic, cardiovascular diseases § Lead product for conges?ve heart failure – number 1 cause of hospitaliza?on in industrialized world § Provides Phase 3 clinical and regulatory exper?se §
Slide 7: Corporate partnerships manage execution risk - Lonza
Corporate partnerships manage execu,on risk -‐ Lonza For personal use only § Our product manufacturing strategy is to ensure: commercial scale-‐up reduced COGS capacity for commercial product supply § Lonza partnership provides global process development & manufacturing capability § Exclusive a
Slide 8: Product Pipeline
For personal use only Product Pipeline 8
Slide 9: Platform Delivers Multi-Product Pipeline
PlaYorm Delivers Mul,-‐Product Pipeline For personal use only 9
Slide 10: Products for intravenous administration
Products for intravenous administra,on For personal use only Intravenous products to treat prevalent systemic disorders affec,ng the metabolic, inflammatory and immune systems § Type 2 early diabetes § Kidney failure and cardiovascular complica?ons § liver fibrosis Inflammatory/immune mediated diseas
Slide 11: Integrated Metabolic Mechanisms of Action of MPCs
Integ rated Metabolic Mec hanis ms of Ac tion of MP C s For personal use only Pre-Osteoblast Osteoblast Oc n uc OC N Adipo1R, 2R Adiponec tin ↑Insulin sensitivity B one-‐marrow derived MP C s ↓HGP Adiponec tin ↓Lipotoxicity A dipoc ytes Other potential MPC effects in diabetes: anti-inflammation, Im
Slide 12: Intravenous delivery - Type 2 diabetes
Intravenous delivery -‐ Type 2 diabetes For personal use only • Randomized, placebo-‐controlled Phase 2 trial in 60 pa?ents with type 2 diabetes ac?vely recrui?ng under FDA guidance • Pa?ents evaluated over 12 weeks for blood glucose control and inflammatory markers such as C-‐reac?ve protein (C-
Slide 13: Intravenous delivery – renal complications of diabetes
Intravenous delivery – renal complica,ons of diabetes For personal use only • Plan to evaluate whether single dose of MPCs can stabilize or reverse end-‐stage kidney disease • Nearly 10% annual rate of cardiovascular disease and death in diabe?c pa?ents with end-‐stage kidney disease • Non-‐human
Slide 14: Intravenous delivery – Immune-mediated diseases
Intravenous delivery – Immune-‐mediated diseases • Preclinical data indicate MPCs have immunomodulatory proper?es For personal use only • Single intravenous injec?on may provide sustained benefits for immune-‐ mediated diseases • Mechanism of ac?on (MOA) is unique as shuts down mul?ple cytokine pat
Slide 15: Products for local administration - cardiovascular
Products for local administra,on -‐ cardiovascular For personal use only With Teva, developing therapies for cardiovascular diseases including conges,ve heart failure (CHF) and acute myocardial infarc,on (AMI) • Phase 2 trial for CHF showed pa?ents treated with single intra-‐cardiac injec?on of hi
Slide 16: Products for local administration – spine disease
Products for local administra,on – spine disease For personal use only Diseases of the spine represent largest growing market segment in orthopedics • Spinal fusion product for pa?ents with advanced disc degenera?on who need surgery Ø Phase 2 lumbar and cervical spinal fusion trials completed enrol
Slide 17: Other products – eye diseases and bone marrow transplantation
Other products – eye diseases and bone marrow transplanta,on For personal use only Developing stem cell therapeu,c product for trea,ng various vascular and inflammatory diseases of the eye including wet and dry age-‐related macular degenera,on (AMD) • Wet and dry AMD are the major causes of blindnes
Slide 18: The year ahead, what we expect
The year ahead, what we expect: For personal use only § Commencement of Phase 3 trial for conges?ve heart failure involving an early interim analysis to evaluate evidence of efficacy § Con?nued recruitment in Phase 2 trial for AMI pa?ents § Clinical results in Phase 2 trials with early type 2 diabe
Slide 19: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies
Mesoblast — Bell Potter Life Sciences Conference 2012 on 6ix